KR101511364B1 - Herbal Extract Composition for Prevention or Treatment of Obesity and Metabolic Syndrome Using Herbal Extract - Google Patents

Abstract

The present invention contains a complex extract of more specifically relates to a composition for preventing or treating with a compound saengyakjae obesity and metabolic syndrome is ohsuyu (Evodiae Fructus), baekmogeun (Imperatae Rhizoma) and cheongpi (Citrus Unshiu Markovich) as an active ingredient Obesity and metabolic syndrome (Syndrome X).

Herbal medicine, obesity, metabolic syndrome,

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or treating obesity and metabolic syndrome using a combination herbal medicine,

The present invention relates to a composition for preventing or treating obesity and metabolic syndrome using a combined herbal medicine.

Obesity has already been defined as a disease by the World Health Organization (WHO) in 1996. Approximately 150 million people worldwide have experienced obesity, a health risk factor. Obesity is directly related to various adult diseases, so the need for obesity treatment is urgently needed. In addition, the market size of obesity treatment drugs is on the rise due to the improvement of economic level and interest in appearance.

The market for obesity drugs was estimated at about $ 1.3 billion in 2000 and is expected to reach $ 8 billion by 2010, with a CAGR of 20%. Currently, there are more than 10 kinds of obesity drugs that are currently undergoing clinical trials or awaiting approval from the FDA. Xenical and Reductil have been approved by the US FDA and have been introduced in Korea and rapidly spreading. 2001 Winter].

The hazard of obesity is that obesity itself causes constipation, indigestion and gastrointestinal disturbance due to the pressure of abdomen caused by adipose tissue, which is a risk factor for many adult diseases. Obesity is known to be the source of all diseases including cancer, arteriosclerosis, heart disease, hypertension, diabetes, and other diseases and complications. In 1996, the World Health Organization (WHO) warned that obesity is a disease that requires treatment. A study of 750,000 people found that men and women over 40% of their average body weight had a 1.9-fold increase in mortality rates compared to those of normal weight. Recently, it has been shown that obesity is the cause of the so-called metabolic syndrome (X-syndrome), which is considered to be the pre-existing stage of diabetes and hypertension, and the prevalence of it is 1/4 of the world's population The severity is growing.

Metabolic syndrome is characterized by insulin resistance, abdominal obesity, hyperlipidemia, hypertension, hyperglycemia, and is a common symptom in obesity. The World Health Organization warns the American Medical Association (JAMA) that anyone with such a metabolic syndrome is likely to become a diabetic, stroke or heart disease patient.

Patients with three or more of the following five symptoms are called metabolic syndrome patients.

(1) Waist circumference ------- (Male) More than 100 cm (Female) More than 88 cm

(2) Blood Pressure ----------- 135/80 mmHg or more

(3) Blood sugar ----------- 110 (fasting) mg / day or more

(4) Neutral lipid ------- 150 mg / dl or more

(5) HDL levels ----- (Male) 40 mg / dl or less (female) 50 mg / dl or less

It is obvious that the metabolic syndrome is ultimately derived from obesity. At this time, the management of obesity is recognized more importantly in relation to the occurrence of the metabolic syndrome patient, which is the prevalent stage of the disease in the future.

Obesity is an accumulation of excess fat in the body, and the cause of accumulation of fat in the body is excessive intake of carbohydrates (carbohydrates) or excessive intake of fat. The mechanism that reaches obesity is that the sugar contained in the food is digested and becomes monosaccharide, absorbed into the body through the small intestine, and the insulin which is secreted by the stimulus increases the blood sugar, and the monosaccharide Fat cells will be accepted and converted to fat. In addition, fat, which is the highest calorific value among food components, is decomposed by pancreatic lipase and absorbed through the small intestine, resulting in an increase in stored calories due to an excessive intake calorie. That is, obesity is caused by excessive fat intake.

Therefore, studies on various anti-obesity agents are under way based on the idea of generating an anti-obesity effect by inhibiting a part of the pathway of those reaching obesity.

A cholesterol-lowering action, a cholesterol-lowering action, a cholesterol-lowering action, a cholesterol-lowering action, or a cholesterol-lowering action that inhibits a pathway leading to obesity by an excessive sugar intake inhibitory action, It is believed that it is possible to prevent and improve obesity by the action of lipid peroxidation, the action of lowering triglyceride in blood, or the lipase inhibiting action, and research on the pharmaceutical ingredient having these actions is continuing.

Rapid postprandial hyperglycemia and excessive insulin secretion resulting from excessive intake of carbohydrates (carbohydrates) cause diabetes or hyperlipemia in addition to obesity [pharmacology and therapy Vol. 19, No. 10 Oct. 274, 1991], it is known that diabetes or hyperlipemia can be prevented and improved by inhibiting carbohydrate digestive enzymes. Therefore, it is considered that a carbohydrase digestive enzyme inhibitor, monosaccharide absorption inhibitor, or a glycemic inhibitor is useful as an anti-diabetic agent, an anti-hyperlipidemic agent, or an atherosclerosis agent. As carbohydrate digestive enzyme inhibitors currently used as pharmaceuticals, there are α-glucosidase inhibitor acarbose (Bayer Pharmaceutical Co., Ltd.) or postprandial hyperglycemia inhibitor borgribose (AO-128, Takeda Pharmaceuticals Co., Ltd.). They have been shown to inhibit postprandial hyperglycemia in animal studies and clinical trials, and have also been shown to be effective against anti-obesity and anti-diabetes [Res. Exp. Med.vol. 175, 87 (1979), Japanese Journal of Agricultural Chemistry vol. 63, 217 (1989), New Current vol. 6, 2 (1995). In addition, methods of inhibiting the pathway leading to obesity by intake of fat (triglycerides) include cholic acid adsorption excretion, cholesterol lowering, blood triglyceride lowering, and lipase inhibition. There are colestyramine, a treatment for hypercholesterolemia, which is an anion exchange resin. The anion exchange resin is orally administered to the anion exchange resin for long-term circulation (intestinal hepatic circulation) (Maquinosaora, Taisha, vol. 24, No. 8, 685-692, 1987], adsorbs and fixes the intestinal cholic acid to inhibit reabsorption of cholic acid, and promotes the conversion of cholesterol to cholic acid in the liver, thereby lowering the blood cholesterol concentration. However, the use of cholestyramine caused 9 g to be suspended in 100 mL of water, so that a single dose was very large, and when taking it, the rough and unpleasant texture of the resin remained in the mouth, There was a problem.

Many chemically synthesized compounds having various actions as described above are reported and used as medicines. However, they have a disadvantage that they have a large dose or an unpleasant feeling when they are taken. Also, since they are chemically synthesized compounds, There were cases where the safety was uneasy.

Therefore, due to such safety problems, product development using natural products is increasing both domestically and abroad.

Particularly, it is possible to use a plant such as Cocis semen, Dioscoreae rhizoma, Platycodi radix, Schizandrae fructus, Citus unshiu Markovich, Aloe vera, Adenophorae radix, A drug for suppressing obesity consisting of several extracts of herbal medicine alone or a mixture thereof has been developed. In addition, JP2007-0042755 discloses a composition for inhibiting or treating obesity using a ginseng component, and a composition for preventing or treating obesity or hyperlipidemia using the Puerariae radix has been registered in KR0733336.

However, in the case of such a product derived from a natural product so far known, the material is inevitably very expensive, and it is often necessary to ingest a large amount to obtain an appropriate effect, or to suppress actual obesity and to prevent hyperlipidemia.

Therefore, there is a need to research and develop a new herbal composition which is a natural material, is easy to obtain, and can exhibit a more complex effect.

In addition, the applicant of this patent has registered a patent for a composition (or extract) for the treatment and inhibition of obesity using herbal medicine such as white mugwort through registration papers KR0573590, KR0573591 and KR0573592, Lt; RTI ID = 0.0 > of the present invention. ≪ / RTI >

Thus, the inventors of the present invention confirmed that the combined extracts of crude oil, crude oil, white mugwort, and cheongpyugum were effective in inhibiting weight gain, reducing abdominal fat, and improving the levels of neutral lipids and blood glucose. In addition, the in vitro test confirmed the effect of increasing the activity of the AMPK enzyme, which is a biomarker related to obesity and diabetes mellitus, and confirming the effect of increasing glucose uptake ability in muscle and adipocytes.

Accordingly, it is an object of the present invention to provide a composition for the prevention and treatment of obesity and metabolic syndrome which comprises as an active ingredient a complex extract of Evodiamine Fructus , Citrus Unshiu Markovich and Imperatae Rhizoma.

Further, the present invention has another object to provide a health food containing the complex extract.

It is an object of the present invention to provide a composition for the prevention and treatment of obesity and metabolic syndrome containing an extract of Evodiamine Fructus , Citrus Unshiu Markovich and Imperatae Rhizoma as an active ingredient.

It also includes a health food containing the complex extract.

The complex extract according to the present invention promotes the expression of genes involved in the prevention of obesity and metabolic syndrome and the treatment of obesity in cells, and it is shown that the mice having a high fat diet have a very excellent weight gain inhibitory effect and a high level of neutral lipids and blood glucose And exhibits an excellent effect of glucose uptake in muscle cells and adipocytes.

Hereinafter, the present invention will be described in more detail.

In order to accomplish the above object, the present invention provides a composition for preventing and treating obesity and metabolic syndrome comprising an extract of Evodiamine Fructus , Citrus Unshiu Markovich and Imperatae Rhizoma as an active ingredient .

In the present invention, it is preferable that 0.1 to 10 parts by weight of the extract of Cheongwipyong and 0.1 to 30 parts by weight of Baekmooru extract are mixed with 1.0 part by weight of the crude oil extract to use the combined extract as an active ingredient.

The complex extract according to the present invention can be prepared by first obtaining by cold water extraction, hot water extraction, solvent extraction or the like according to a conventional method, followed by drying and mixing in the above ratios. In this case, each of the herbal medicines may be extracted in different ways. For example, it can be produced by the following method.

First, prepare each of the sour milk, the chewy and the white scallion that have been cut and cut to a suitable size. In this case, 0.1 to 10 parts by weight of chewing gum and 0.1 to 30 parts by weight of white clover are used relative to 1 part by weight of the crude oil. After 10 ~ 100 times of aqueous alcohol solution of each herbal medicine is added, extraction is carried out at 70 ~ 100 ° C for 4 ~ 8 hours, followed by rapid freezing at -50 ~ -30 ° C for 10 ~ 20 hours, Vacuum-dried for 40 hours and then pulverized to prepare a dry powder. Then, the dry powder of each herb medicine is mixed according to the above ratio to obtain a combined extract powder according to the present invention. Of course, it is also possible to obtain the combined extract powder according to the present invention by previously investigating the solid content of each herbal medicine extract before drying, mixing the extracts so as to have the above ratios, and collectively drying them.

Meanwhile, the complex extract according to the present invention may be obtained by first collecting the herbal composition dried at a calculated ratio so that the ratio is finally obtained, and collecting it collectively. To this end, a mixture of 1.0 part by weight of the dried sour milk extract, 0.1 to 10 parts by weight of the dried celery extract and 0.1 to 30 parts by weight of the dried white rape extract is mixed with each component by a conventional method such as cold water extraction, hot water extraction or solvent extraction May be extracted and then used as it is, or may be used as a powder by lyophilization. For example, it can be produced by the following method. First, sour oil, chewy gum, and white scarf, which have been sorted and sized appropriately, are mixed according to the mixing ratio. The mixture is subjected to extraction at a temperature of 70 to 100 ° C for 4 to 8 hours, followed by rapid freezing at -50 to -30 ° C for 10 to 20 hours, followed by rapid freezing at a pressure of 0.1 to 0.5 Torr, Vacuum-dried for a time, and then pulverized to obtain a complex extract powder according to the present invention.

As a result of many experiments and examinations, the inventors of the present invention have found that the best herbal composition can be obtained only by the above-mentioned content ratio.

In addition, the complex extract according to the present invention can increase intracellular AMPK activity and increase intracellular glucose uptake as shown in the following preparations and examples, and can be used as a conventional conventional herbal medicine or a commercial synthetic drug for obesity treatment and inhibition And it shows a remarkably excellent and safe effect.

Accordingly, the compound extract of the present invention can be manufactured as a pharmaceutical.

The combined extract of the present invention can be administered to mammals such as rats, livestock, and humans in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The present invention also provides a health functional food comprising the composition and the pharmaceutically acceptable food supplementary additive exhibiting the preventive and therapeutic effect of obesity and metabolic syndrome. Foods to which the compound extract can be added include, for example, various foods, beverages, gums, tea, vitamin complexes, and health functional foods.

In addition, the present invention includes a health food for improving obesity and metabolic syndrome which contains a complex extract as an active ingredient. In addition to the above-mentioned complex extract, the health food may contain a variety of auxiliary medicinal preparations, vitamins, minerals, dietary fiber and other medicinal-food adjuvants (for example, excipients, enhancers, coating agents, etc.)

It can also be added to foods or beverages for the purpose of preventing and treating obesity and metabolic syndrome. In this case, the amount of the complex extract in the food or beverage may be generally 0.0001 to 100% by weight, preferably 80% by weight or less of the total food weight of the health food of the present invention, and 100 ml Based on the total weight of the composition, of 0.0001 to 10 g, preferably 5.0 g or less.

Hereinafter, the present invention will be described in more detail in Examples and Application Examples. The following examples are intended to illustrate the present invention in further detail and do not limit the scope of the present invention. It will be apparent to those skilled in the art that various embodiments and applications not shown in the following embodiments are possible.

Preparation Example: Preparation of complex extract

(1) 1 Kg of dry sour oil, white mud, and chewy, which had been previously screened and cut to a proper size, were mixed with 10 times by weight 70% ethanol aqueous solution and then heated and subjected to primary extraction at 85 ° C for 6 hours. Then, the primary filtrate was collected separately, and a 10-fold weight of 70% ethanol aqueous solution was further added to the filtered herbal medicine, followed by heating and secondary extraction at 85 ° C for 6 hours. After filtration, a secondary filtrate was obtained, rapidly frozen at 70 ° C for 12 hours with a primary filtrate, vacuum-dried for 36 hours or more at a pressure of 0.23 torr or less, and pulverized to obtain respective dry powders.

The resulting crude extracts were mixed with 1 part by weight of white mugwort extract and 3 parts by weight of a mugwort extract to obtain a combined extract powder of the present invention.

(2) The extraction efficiency of each herbal medicine was analyzed in advance, and each dry herbal medicine was mixed in the final extract. That is, the dry sour oil, the white mud, and the chewiness, which had been previously screened and cut to a proper size, were mixed, and a 10-fold weight 70% aqueous ethanol solution was poured thereon and then heated and subjected to primary extraction at 85 ° C for 6 hours. Then, the primary filtrate was collected separately, and a 10-fold weight of 70% ethanol aqueous solution was further added to the filtered herbal medicine, followed by heating and secondary extraction at 85 ° C for 6 hours. Thereafter, a secondary filtrate was obtained. After rapid freezing at 70 ° C for 12 hours with a primary filtrate, it was vacuum-dried for 36 hours or more at a pressure of 0.23 torr or lower and then pulverized to obtain respective dry powders.

(3) As a result of analysis of various surface components and in vitro and in vivo test results, the herbal composition according to the present invention prepared by the above two methods was identified as the same. Therefore, in the following experiments, the two methods were used in the examples without distinction.

Example 1: Measurement of AMPK enzyme activity of a complex extract

AMPK activity was examined over time after treating the natural extract mixture with the cells. Activation of AMPK enzyme increases glucose uptake, inhibits fatty acid synthesis, and promotes fatty acid oxidation. Thus, the present invention can confirm the possibility of preventing or treating obesity and metabolic syndrome of the present invention.

As can be seen from FIG. 1, the complex extract of the present invention shows a significant increase in AMPK enzyme expression as compared with the positive control AICAR.

Example 2: Effect of compound extract on weight gain in an animal model and its effect on fat accumulation and fat and sugar in plasma

(1) Experimental animals were 20 ~ 25 g 6-week-old C57BL / 6 mice purchased from a central laboratory animal, and allowed to eat food and water freely in the animal room. After one week, the animals were divided into 4 groups as follows: Regular Diet, RD) and 45% High Fat Diet (HFD). After 6 weeks, the mice were separated again according to their weight and 5 mice were placed in the cage so that the average of HFD was 36-37 g. The mice were divided into two cages (10 mice) in one group. The average weight of normal diet was 27 g. The combination extract of the present invention was orally administered to a high fat diet mouse for 10 weeks each day, and weight change and intake of the mice were observed.

RD: Controlled diet with normal diet, HFD: High fat diet with 45% high fat diet control group, HFD + complex extract: High fat diet + combination extract (500 mg / kg), HFD + Sibutramine: High fat diet This + sibutramine (2 mg / kg) is used as a positive control.

(2) In order to examine the therapeutic effect of metabolic syndrome, the compound extract of the present invention was administered at a dose of 500 mg / kg to obesity-induced mice (diet induced obesity) Were orally administered with a high fat diet for 10 weeks. The body weight was measured twice a week and the food intake was measured once every two days. After 10 weeks, blood was collected from the eyeballs of the mice, and the blood was collected. Each tissue of the mice was extracted and weighed and used for the analysis.

(3) Sampling and analysis of blood indicators

At the last sacrifice, blood was collected from the orbital vein, each tissue was extracted and weighed and used for analysis. Blood samples were collected by centrifugation at 1,500 rpm for 30 minutes, followed by aspiration of triglycerides, glucose, and cholesterol (cholesterol) kit was purchased and measured with an ELISA reader.

(4) Experimental results

① weight change

FIG. 2 shows the results of comparing weight change patterns between groups for 10 weeks. As shown in FIG. 2, when a sample was administered after inducing obesity for 6 weeks in a high-fat diet, the mouse body weight temporarily decreased until two weeks. This may be due to mouse stress caused by oral administration. The body weight was increased again from the third week and significantly increased from 500 mg / kg of the compound extract to the control group from 5th week. This effect was continued for 10 weeks. The body weight of the high-fat diet group (HFD) increased to 46.5 ± 1.5 compared with the diet group (RD, 29.5 ± 1.2) at 10 weeks, while the combined extract group had 41.3 Respectively. On the other hand, the body weight of the sibutramine - treated group, a positive control group, was 43.3 ± 1.7, which was lower than that of the high - fat diet group. As a result of the present experiment, the compound extract of the present invention was found to have an excellent activity for suppressing weight than the positive control.

② Tissue weight analysis

The following Table 1 shows the results obtained after 10 weeks by extracting tissues such as mouse adipose tissue, liver, kidney, spleen, brain, , Kidney, and spleen weight.

In the control group (HFD), the abdominal fat was significantly increased, liver and kidney weight were significantly increased, and the weight of the other organs did not change significantly. In the case of adipose tissue, the high fat diet group showed 4.5 ± 0.5, whereas the fat fat diet group showed 3.2 ± 0.4 fat reduction by 30%.

③ Blood analysis

The following Table 2 shows the results of the oral administration of the composition to the diet-induced obesity (Diet-induced obesity) for 10 weeks, followed by overnight (8 hours) fasting and then the blood of the mouse obtained from the orbital vein was centrifuged to collect plasma, And cholesterol. (HFD) was significantly higher than that of the normal dietary group (RD) in the control group (HFD) compared with the control group (123 mg / kg) Neutral lipid lowering effect. In the case of blood glucose, the control group (HFD) showed a significant increase at 255.6 ± 30.1 mg / dl compared with the normal dietary group (RD), whereas the composition administration group showed 204.1 ± 14.5 mg / dl at 500 mg / Compared with the control group. In the case of neutral lipids and blood sugar, high-fat diet was similar to body weight, but the effect of cholesterol on cholesterol was not significant.

Thus, it has been confirmed that the herbal composition of the present invention can be used not only for weight reduction but also for reduction of neutral lipid and blood glucose level.

Example 3: Investigation of glucose uptake ability in muscle cells and adipocytes of a compound extract

(1) Investigating the possibility of development of three herbal composition compositions according to the present invention as a therapeutic agent for obesity and diabetes by investigating glucose uptake efficiency in C2C12 myocardial cells and 3T3 L1 adipocytes.

(2) Increasing glucose uptake ability of compositions in C2C12 myocytes

The complex extract of the present invention was dissolved in water and treated with cells at different concentrations for 24 hours, MTT analysis was performed to select the highest cytotoxic concentration, and glucose uptake ability was examined in C2C12 myocytes (FIG. 3). The complex extract of the present invention was found to increase glucose uptake better than insulin at a dose of 100 ㎍ / mL, and thus it is considered to be effective for glucose uptake.

(3) glucose absorption effect of the composition in 3T3 L1 adipocytes

The combined extract of the present invention was dissolved in water to examine the effect of 3T3L1 adipocytes on glucose uptake at a low cytotoxicity concentration (Fig. 4). The combined extract of the present invention was found to increase glucose uptake to a similar extent as 100 nM insulin, indicating that it has an excellent glucose uptake efficiency.

In conclusion, the compound extract according to the present invention has been shown to inhibit weight gain and improve neutral lipid and blood glucose levels through animal experiments. In vitro tests have shown that the AMPK enzyme activity, which is a biomarker for prevention or treatment of obesity and metabolic syndrome, And increased glucose uptake in muscle and adipocytes.

Thus, it can be confirmed that the compound extract according to the present invention is useful for the treatment and prevention of diseases associated with obesity and metabolic syndrome.

Formulation Example 1: Preparation of Injection

1) complex extract of Preparation Example 1 ... 100 mg

pH adjusting agent .................................... Amount

The above components were mixed, prepared by a conventional method, filled in a 2 ml volume ampoule and sterilized to prepare an injection.

Formulation Example 2: Preparation of tablets

1) complex extract of Preparation Example 1: 50 mg

Lactose ........................................ 125 mg

Microcrystalline Cellulose ............................ 75 mg

Magnesium stearate .......................... Amount

The above components were mixed and tablets were prepared by tableting according to a conventional method for producing tablets.

Formulation Example 3: Preparation of capsules

1) complex extract of Preparation Example 1 ... 100 mg

Lactose ....................................... 125 mg

Starch ....................................... 125 mg

Talc ........................................

Magnesium stearate .......................... Amount

The above components were mixed and filled into capsules according to a conventional preparation method of capsules to prepare capsules.

Formulation Example 4: Preparation of a liquid preparation

1) complex extract of Preparation Example 1 ... 1000 mg

Per minute ......................................... 20 g

Is isomerization ..................................... 20 g

Lemon flavor ......................................

Purified water was added to adjust the total volume to 1000 ml. The above components were mixed in accordance with a conventional method for producing a liquid agent to prepare a liquid agent.

Formulation Example 5: Preparation of Health Functional Foods

1) complex extract of Preparation Example 1: 100 mg

Vitamin A (0.275 mg as retinyl palmitate) ......... 500 IU

DL-alpha-tocopherol .......................................... 20 mg

Vitamin B1 Nitrate ......................................... 1.5 mg

Vitamin B2 ................................................ 1.8 mg

Pyridoxine hydrochloride ............................................. 2 mg

Vitamin B12 ................................................ .2 [mu] g

Biotin ................................................. 0.1 mg

Nicotinic acid amide ............................................. 5 mg

Folic acid ................................................. .... 0.1 mg

Calcium pantothenate ............................................... 5 Mg

Vitamin C ................................................ ..50 mg

Glycerol ginseng calcium (4.76 mg as calcium) ....................... 25 mg

Iron sulfate (5.0 mg as iron) ................................... 15.45 mg

Zinc sulfate (1.0 mg as zinc) .............................. 2.74 mg

Copper sulfate (0.5 mg as copper) ................................. 1.256 mg

Manganese sulfate (0.5 mg as manganese) .............................. 1.54 mg

Although the compound extract of the present invention and the vitamin and mineral are relatively mixed with a suitable ingredient for health functional food, the compounding ratio of the compound extract may be arbitrarily changed, After mixing the above ingredients, granules may be prepared and used in the manufacture of a health functional food composition according to conventional methods.

Formulation Example 6: Preparation of health drinks

1) complex extract of Preparation Example 1 ... 500 mg

Citric acid .................................... 1000 mg

Oligosaccharide .................................... 20 mg

Taurine ..................................... 100 mg

Purified water was added to adjust the total volume to 900 ml. It is prepared according to the usual health drink manufacturing method.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

FIG. 1 shows the effect of the AMPK enzyme activity of the complex extract according to the present invention on an animal model of obesity.

Fig. 2 shows changes in body weight of experimental mice for 10 weeks.

FIG. 3 is a graph showing the increase in glucose uptake ability in muscle cells of the combined extract according to the present invention.

FIG. 4 is a graph showing an increase in glucose uptake ability in mast cells of the combined extract according to the present invention.

Claims (5)

The composition according to the present invention contains 0.1 to 10 parts by weight of the extract of Cheongwippe and 0.1 to 30 parts by weight of the extract of Baekmu gum, based on 1.0 part by weight of the crude oil extract, as an active ingredient, a combined extract of Evodiamine Fructus, Citrus Unshiu Markovich and Imperatae Rhizoma. And a pharmaceutically acceptable carrier and / or excipient. delete The composition according to claim 1, wherein the composition has the effect of preventing and treating obesity and metabolic syndrome caused by increased intracellular AMPK activity and glucose uptake ability. Wherein the combined extract of Evodiamine Fructus, Citrus Unshiu Markovich and Imperatae Rhizoma is contained as an active ingredient, wherein 0.1 to 10 parts by weight of the extract of Cheongwippe and 1 to 10 parts by weight of Baekmooru extract And 0.1 to 30 parts by weight of a nonionic surfactant. delete

Images